Actively Recruiting
A Study of SPY002-072 in Healthy Volunteers
Led by Spyre Therapeutics, Inc. · Updated on 2024-11-27
56
Participants Needed
2
Research Sites
89 weeks
Total Duration
On this page
Sponsors
S
Spyre Therapeutics, Inc.
Lead Sponsor
A
Altasciences Company Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants.
CONDITIONS
Official Title
A Study of SPY002-072 in Healthy Volunteers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy men and women
- Willing and able to attend all required visits and comply with study procedures
- Able to remain at the study site during the confinement period and return for outpatient visits
You will not qualify if you...
- Participation in more than one cohort of the study
- Presence of any clinically significant abnormality or disease
- History of illicit drug use, cannabis/cannabinoid use, harmful alcohol use, alcoholism, or smoking/nicotine use within 3 months prior to first dose
- History of severe allergic reactions or hypersensitivity
- Donation or loss of 1 or more units of whole blood within 1 month before dosing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Spyre Site 2
Cypress, California, United States, 90630
Not Yet Recruiting
2
Spyre Site 1
Montreal, Quebec, Canada, H3P 3P1
Actively Recruiting
Research Team
M
Medical Director, Clinical Development
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here